Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VS-7375 in previously treated advanced KRAS G12D-mutated non-small cell lung cancer
2026-526472-23-00Phase 2Authorised
- Sponsor
- Verastem Oncology
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of GFH375 in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Verastem Oncology. Primary endpoints: Confirmed objective response rate, Intracranial objective response rate and 1 more. Planned start Oct 2026; status: authorised.
02
Drugs
GFH375
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2026-526472-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526472-23-00.